- Home
- INTS vs CRWD Comparison
INTS vs CRWD Comparison
Compare INTS & CRWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INTS
- CRWD
- Stock Information
- Founded
- INTS 2012
- CRWD 2011
- Country
- INTS United States
- CRWD United States
- Employees
- INTS 16
- CRWD N/A
- Industry
- INTS Biotechnology: Pharmaceutical Preparations
- CRWD EDP Services
- Sector
- INTS Health Care
- CRWD Technology
- Exchange
- INTS Nasdaq
- CRWD Nasdaq
- Market Cap
- INTS 30.8M
- CRWD N/A
- IPO Year
- INTS 2023
- CRWD 2019
- Fundamental
- Price
- INTS $2.06
- CRWD $361.13
- Analyst Decision
- INTS Strong Buy
- CRWD Buy
- Analyst Count
- INTS 3
- CRWD 46
- Target Price
- INTS $8.50
- CRWD $400.79
- AVG Volume (30 Days)
- INTS 38.4K
- CRWD 5.2M
- Earning Date
- INTS 03-13-2025
- CRWD 03-04-2025
- Dividend Yield
- INTS N/A
- CRWD N/A
- EPS Growth
- INTS N/A
- CRWD N/A
- EPS
- INTS N/A
- CRWD N/A
- Revenue
- INTS N/A
- CRWD $3,953,624,000.00
- Revenue This Year
- INTS N/A
- CRWD $23.41
- Revenue Next Year
- INTS N/A
- CRWD $21.64
- P/E Ratio
- INTS N/A
- CRWD N/A
- Revenue Growth
- INTS N/A
- CRWD 29.39
- 52 Week Low
- INTS $1.50
- CRWD $200.81
- 52 Week High
- INTS $5.28
- CRWD $455.59
- Technical
- Relative Strength Index (RSI)
- INTS 46.37
- CRWD 43.94
- Support Level
- INTS $1.88
- CRWD $353.03
- Resistance Level
- INTS $2.18
- CRWD $392.69
- Average True Range (ATR)
- INTS 0.21
- CRWD 14.99
- MACD
- INTS -0.01
- CRWD 1.34
- Stochastic Oscillator
- INTS 39.73
- CRWD 35.37
About INTS Intensity Therapeutics Inc. Common stock
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.